Transgenic Group Inc.
Research Transgenic Group Inc. (2342.T) on Bullrun: market cap JPY 3.73B, P/E 117.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2342.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 3.73B
- P/E117.3
- Financial periodFY2026
- RevenueJPY 13.17B
- Revenue growth1.3%
- Net income-JPY 77.27M
- Free cash flow-JPY 42.55M
- Gross margin18.5%
Valuation Snapshot
latest market cap is JPY 3.73B; P/E is 117.3.
Peer valuation comparison
Latest P/E is 117.28x versus a Healthcare sector median of 21.69x (440.6% above).
Latest P/E is 117.28x versus a Japan median of 14.28x (721.5% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 13.17B | -JPY 77.27M | -JPY 42.55M | 18.5% | -4.64 | JPY 2.13B | JPY 2.09B | JPY 4.78B |
| FY2025 | JPY 13.01B | -JPY 1.09B | -JPY 81.35M | 16.7% | -65.51 | JPY 2.56B | JPY 2.58B | JPY 4.76B |
| FY2024 | JPY 13.08B | JPY 4.09M | -JPY 658.12M | 17.2% | 0.24 | JPY 2.48B | JPY 2.22B | JPY 5.89B |
| FY2023 | JPY 11.43B | -JPY 409.67M | -JPY 1.74B | 17.5% | -24.32 | JPY 3.46B | JPY 2.42B | JPY 6.02B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 3.73B | 117.3 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
| Year | Dividends/share |
|---|---|
| FY2024 | 3 JPY |
| FY2023 | 5 JPY |
About Transgenic Group Inc.
Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment and Consulting Business segments. The company provides analysis of the function of individual genes in individuals, elucidation of the relationship between genes and pathology, production of disease model mice, gene expression analysis, and antibody production; clinical trials for pharmaceutical agents, such as bioequivalence studies;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Transgenic Group Inc.'s market cap?
Transgenic Group Inc.'s market capitalization is JPY 3.73B.
What is Transgenic Group Inc.'s P/E ratio?
Transgenic Group Inc.'s price-to-earnings (P/E) ratio is 117.3.
What does Transgenic Group Inc. do?
Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment and Consulting Business segments.